- Home
- RNTX vs CCEL Comparison
RNTX vs CCEL Comparison
Compare RNTX & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNTX
- CCEL
- Stock Information
- Founded
- RNTX 2001
- CCEL 1989
- Country
- RNTX United States
- CCEL United States
- Employees
- RNTX N/A
- CCEL N/A
- Industry
- RNTX Biotechnology: Pharmaceutical Preparations
- CCEL Managed Health Care
- Sector
- RNTX Health Care
- CCEL Health Care
- Exchange
- RNTX Nasdaq
- CCEL Nasdaq
- Market Cap
- RNTX 44.2M
- CCEL 51.9M
- IPO Year
- RNTX N/A
- CCEL 1997
- Fundamental
- Price
- RNTX $1.74
- CCEL $6.35
- Analyst Decision
- RNTX
- CCEL Strong Buy
- Analyst Count
- RNTX 0
- CCEL 1
- Target Price
- RNTX N/A
- CCEL $8.50
- AVG Volume (30 Days)
- RNTX 25.1K
- CCEL 15.1K
- Earning Date
- RNTX 05-14-2025
- CCEL 04-14-2025
- Dividend Yield
- RNTX N/A
- CCEL 3.92%
- EPS Growth
- RNTX N/A
- CCEL N/A
- EPS
- RNTX N/A
- CCEL 0.05
- Revenue
- RNTX N/A
- CCEL $31,986,106.00
- Revenue This Year
- RNTX N/A
- CCEL $2.21
- Revenue Next Year
- RNTX N/A
- CCEL $0.98
- P/E Ratio
- RNTX N/A
- CCEL $129.01
- Revenue Growth
- RNTX N/A
- CCEL 2.05
- 52 Week Low
- RNTX $1.61
- CCEL $5.75
- 52 Week High
- RNTX $7.42
- CCEL $9.50
- Technical
- Relative Strength Index (RSI)
- RNTX N/A
- CCEL 41.09
- Support Level
- RNTX N/A
- CCEL $6.13
- Resistance Level
- RNTX N/A
- CCEL $6.65
- Average True Range (ATR)
- RNTX 0.00
- CCEL 0.37
- MACD
- RNTX 0.00
- CCEL 0.04
- Stochastic Oscillator
- RNTX 0.00
- CCEL 42.86
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03, LTI-01, and others.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.